Carregant...
Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes
Exenatide once weekly (EQW), the first glucose-lowering agent for type 2 diabetes that is dosed one time per week, contains exenatide encapsulated in microspheres of a dissolvable matrix, which release active agent slowly and continuously into the circulation following subcutaneous injection. In two...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove Medical Press
2013
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3840776/ https://ncbi.nlm.nih.gov/pubmed/24285927 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S48837 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|